Article in Blood cancer journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors at 3 institutions in 1 country.
Maria Alice V WillrichDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, US. willrich.mariaalice@mayo.edu.ORCID 0000-0002-9318-7091
David L MurrayDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, US.ORCID 0000-0003-1720-335X
Sandra C BryantDepartment of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, US.
Dirk LarsonDepartment of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, US.ORCID 0000-0002-2970-2124
Vanessa PazdernikDepartment of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, US.
Melissa R SnyderDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, US.
Robert A KyleDivision of Hematology, Mayo Clinic, Rochester, MN, US.
Angela DispenzieriDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, US. Dispenzieri.angela@mayo.edu.ORCID 0000-0001-8780-9512
Mayo Clinic in Arizona · USMayo Clinic in Florida · USMayo Clinic · US
Funding
Trageting the Multiple Myeloma EpigenomeP50CA100707 · NCI · DANA-FARBER CANCER INSTITUTE · PI ANDERSON, KENNETH C., MUNSHI, NIKHIL C. · 2003 to 2023
$45.0M
Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Rafael Fonseca · 2015 to 2026
$25.5M
TISSUE BANK AND CLINICAL/LABORATORY DATABASEP01CA062242 · NCI · MAYO CLINIC ROCHESTER · PI THERNEAU, TERRY M · 1994 to 2009
$12.9M
Prevalence and Progression of Monoclonal GammopathiesR01CA107476 · NCI · MAYO CLINIC ROCHESTER · PI KUMAR, SHAJI KUNNATHU, RAJKUMAR, S VINCENT · 2004 to 2018
$4.6M
CHROMOSOMAL ABNORMALITIES IN MYELOMA AS DETECTED BY FISHR01CA083724 · NCI · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI FONSECA, RAFAEL · 2000 to 2013
$4.0M
Onset and biomarkers for progression of monoclonal gammopathiesR01CA168762 · NCI · MAYO CLINIC ROCHESTER · PI KUMAR, SHAJI KUNNATHU, RAJKUMAR, S VINCENT · 2012 to 2024
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Comparison of two free light chain assays: performance of the involved free light chain ratio and implications for diagnosis of multiple myeloma. · full record | OpenQuestion